益佰制药:2025一季报净利润-0.09亿 同比增长86.76%

Financial Performance - The company reported a basic earnings per share of -0.0120 yuan for Q1 2025, an improvement of 86.05% compared to -0.0860 yuan in Q1 2024, but a decline from 0.0560 yuan in Q1 2023 [1] - The total revenue for Q1 2025 was 5.01 billion yuan, down 12.57% from 5.73 billion yuan in Q1 2024 and significantly lower than 6.84 billion yuan in Q1 2023 [1] - The net profit for Q1 2025 was -0.09 billion yuan, showing an 86.76% improvement from -0.68 billion yuan in Q1 2024, but a decline from 0.44 billion yuan in Q1 2023 [1] - The return on equity for Q1 2025 was -0.38%, an improvement of 83.19% from -2.26% in Q1 2024, but a decrease from 1.44% in Q1 2023 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 25,915.61 million shares, accounting for 32.73% of the circulating shares, with a change of 1,448.6 thousand shares from the previous period [1] - The largest shareholder, Dou Qiling, holds 18,545.76 million shares, representing 23.42% of the total share capital, with no change in holdings [2] - Other notable shareholders include Lü Liangfeng with 2,357.60 million shares (2.98%, increased by 85.4 thousand shares) and Zhang Sufen with 1,433.00 million shares (1.81%, increased by 110.00 thousand shares) [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]